NASDAQ:STSA Satsuma Pharmaceuticals (STSA) Stock Forecast, Price & News $1.05 -0.02 (-1.87%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$1.02▼$1.0850-Day Range$0.66▼$1.0852-Week Range$0.59▼$8.08Volume247,575 shsAverage Volume698,751 shsMarket Capitalization$34.81 millionP/E RatioN/ADividend YieldN/APrice Target$7.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial MediaSustainability Satsuma Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.20 Rating ScoreUpside/Downside604.8% Upside$7.40 Price TargetShort InterestHealthy0.46% of Float Sold ShortDividend StrengthN/ASustainability-1.25Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.82) to ($0.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.33 out of 5 starsMedical Sector116th out of 983 stocksPharmaceutical Preparations Industry45th out of 486 stocks 3.1 Analyst's Opinion Consensus RatingSatsuma Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.40, Satsuma Pharmaceuticals has a forecasted upside of 604.8% from its current price of $1.05.Amount of Analyst CoverageSatsuma Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.46% of the float of Satsuma Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSatsuma Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Satsuma Pharmaceuticals has recently decreased by 58.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSatsuma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSatsuma Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSatsuma Pharmaceuticals has received a 67.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for Satsuma Pharmaceuticals is -1.25. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for STSA on MarketBeat in the last 30 days. This is a decrease of -98% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Satsuma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Satsuma Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.26% of the stock of Satsuma Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Satsuma Pharmaceuticals are expected to decrease in the coming year, from ($0.82) to ($0.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Satsuma Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Satsuma Pharmaceuticals is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSatsuma Pharmaceuticals has a P/B Ratio of 0.92. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Satsuma Pharmaceuticals (NASDAQ:STSA) StockSatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Read More Receive STSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Satsuma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address STSA Stock News HeadlinesMay 22, 2023 | americanbankingnews.comContrasting Satsuma Pharmaceuticals (NASDAQ:STSA) and Catalent (NYSE:CTLT)May 18, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Announces FDA Acceptance of 505(b)(2) NDA for STS101, a Novel and Investigational Dihydroergotamine (DHE) Nasal Powder Product for the Acute Treatment of MigraineJune 2, 2023 | Behind the Markets (Ad)Why did Biden repeal Trump's Executive Order?!" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "May 3, 2023 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRAMay 1, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin NipponApril 25, 2023 | marketwatch.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRAApril 22, 2023 | seekingalpha.comSTSA Satsuma Pharmaceuticals, Inc.April 21, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Announces Three Abstracts Accepted at The 75th American Academy of Neurology Annual MeetingJune 2, 2023 | Behind the Markets (Ad)Why did Biden repeal Trump's Executive Order?!" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "April 20, 2023 | americanbankingnews.comSatsuma Pharmaceuticals (NASDAQ:STSA) Stock Rating Lowered by HC WainwrightApril 19, 2023 | msn.comAfter Satsuma Pharma Rockets 65% on SNBL Bid, There Could Still Be 6X More UpsideApril 18, 2023 | marketwatch.comSatsuma Pharmaceuticals Shares Soar on Shin Nippon Biomedical Deal >STSAApril 17, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Satsuma Pharmaceuticals, Inc. BuyoutApril 17, 2023 | bizjournals.comPeninsula company bets big part of potential $221M sale on future of migraine drugApril 17, 2023 | markets.businessinsider.comSatsuma Pharma Agrees To Be Acquired By Shin Nippon BiomedicalApril 17, 2023 | msn.comSatsuma Skyrockets after Acquisition by Shin NipponApril 17, 2023 | investorplace.comWhy Is Satsuma Pharmaceuticals (STSA) Stock Up 144% Today?April 16, 2023 | finance.yahoo.comSNBL to Acquire Satsuma PharmaceuticalsApril 4, 2023 | americanbankingnews.comBrokers Issue Forecasts for Satsuma Pharmaceuticals, Inc.'s FY2023 Earnings (NASDAQ:STSA)April 3, 2023 | americanbankingnews.comHC Wainwright Reaffirms "Buy" Rating for Satsuma Pharmaceuticals (NASDAQ:STSA)April 2, 2023 | americanbankingnews.comSatsuma Pharmaceuticals' (STSA) "Neutral" Rating Reiterated at MizuhoApril 2, 2023 | americanbankingnews.comSatsuma Pharmaceuticals, Inc. Forecasted to Earn Q1 2023 Earnings of ($0.26) Per Share (NASDAQ:STSA)March 30, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Satsuma Pharmaceuticals (STSA)March 30, 2023 | finance.yahoo.comWe're A Little Worried About Satsuma Pharmaceuticals' (NASDAQ:STSA) Cash Burn RateMarch 29, 2023 | bizjournals.comMigraine drug maker seeks FDA approval and a partner as it cuts jobsMarch 28, 2023 | finance.yahoo.comSatsuma Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business HighlightsFebruary 18, 2023 | marketwatch.com8-K: Satsuma Pharmaceuticals, Inc.See More Headlines STSA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STSA Company Calendar Last Earnings3/28/2023Today6/02/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryRegional Banks SectorMedical Current SymbolNASDAQ:STSA CUSIP85931930 CIK891106 Webwww.satsumarx.com Phone650-410-3200FaxN/AEmployees21Year Founded2016Price Target and Rating Average Stock Price Forecast$7.40 High Stock Price Forecast$15.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+598.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($2.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,060,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-115.24% Return on Assets-102.26% Debt Debt-to-Equity RatioN/A Current Ratio7.44 Quick Ratio7.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book0.93Miscellaneous Outstanding Shares33,150,000Free Float22,809,000Market Cap$35.14 million OptionableNot Optionable Beta0.10 Social Links Key ExecutivesMr. John A. Kollins MBA (Age 59)Pres, CEO & Director Comp: $830kMr. Thomas P. O'Neil (Age 57)Chief Financial Officer Comp: $550.08kDr. Detlef F. Albrecht (Age 61)Chief Medical Officer Comp: $625.97kMr. Mic Iwashima (Age 44)VP & Head of Operations Mr. Robert Schultz (Age 58)Sr. VP & Head of Chemistry, Manufacturing and Controls Dr. Shannon Strom Ph.D. (Age 46)VP & Head of Regulatory Affairs Mr. Robert M. JanoskyChief Commercial OfficerMore ExecutivesKey CompetitorsNeoleukin TherapeuticsNASDAQ:NLTXeFFECTOR TherapeuticsNASDAQ:EFTROrgenesisNASDAQ:ORGSCheckpoint TherapeuticsNASDAQ:CKPTKala PharmaceuticalsNASDAQ:KALAView All CompetitorsInsiders & InstitutionsTwo Sigma Advisers LPBought 121,700 shares on 5/15/2023Ownership: 0.826%Renaissance Technologies LLCSold 89,600 shares on 5/12/2023Ownership: 0.496%Bank of America Corp DEBought 18,321 shares on 5/12/2023Ownership: 0.110%FNY Investment Advisers LLCBought 46,187 shares on 4/12/2023Ownership: 0.139%Braden Michael LeonardBought 150,000 shares on 11/21/2022Total: $106,500.00 ($0.71/share)View All Insider TransactionsView All Institutional Transactions STSA Stock - Frequently Asked Questions Should I buy or sell Satsuma Pharmaceuticals stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Satsuma Pharmaceuticals in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" STSA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in STSA, but not buy additional shares or sell existing shares. View STSA analyst ratings or view top-rated stocks. What is Satsuma Pharmaceuticals' stock price forecast for 2023? 5 Wall Street research analysts have issued 1 year price objectives for Satsuma Pharmaceuticals' shares. Their STSA share price forecasts range from $2.00 to $15.00. On average, they anticipate the company's share price to reach $7.40 in the next year. This suggests a possible upside of 598.1% from the stock's current price. View analysts price targets for STSA or view top-rated stocks among Wall Street analysts. How have STSA shares performed in 2023? Satsuma Pharmaceuticals' stock was trading at $0.90 on January 1st, 2023. Since then, STSA shares have increased by 17.8% and is now trading at $1.06. View the best growth stocks for 2023 here. Are investors shorting Satsuma Pharmaceuticals? Satsuma Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 130,100 shares, a drop of 58.0% from the April 30th total of 310,100 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is presently 0.1 days. Currently, 0.5% of the company's shares are short sold. View Satsuma Pharmaceuticals' Short Interest. When is Satsuma Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our STSA earnings forecast. How were Satsuma Pharmaceuticals' earnings last quarter? Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) posted its earnings results on Tuesday, March, 28th. The financial services provider reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by $0.32. What other stocks do shareholders of Satsuma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Satsuma Pharmaceuticals investors own include Verrica Pharmaceuticals (VRCA), AbbVie (ABBV), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Dynavax Technologies (DVAX), Homology Medicines (FIXX), Gilead Sciences (GILD), Novan (NOVN), Pfizer (PFE) and Akebia Therapeutics (AKBA). When did Satsuma Pharmaceuticals IPO? (STSA) raised $75 million in an IPO on Friday, September 13th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, SVB Leerink and Evercore served as the underwriters for the IPO. What is Satsuma Pharmaceuticals' stock symbol? Satsuma Pharmaceuticals trades on the NASDAQ under the ticker symbol "STSA." Who are Satsuma Pharmaceuticals' major shareholders? Satsuma Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Two Sigma Advisers LP (0.83%), Renaissance Technologies LLC (0.50%), FNY Investment Advisers LLC (0.14%) and Bank of America Corp DE (0.11%). Insiders that own company stock include Braden Michael Leonard, Commodore Capital Lp and Thomas P O'neil. View institutional ownership trends. How do I buy shares of Satsuma Pharmaceuticals? Shares of STSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Satsuma Pharmaceuticals' stock price today? One share of STSA stock can currently be purchased for approximately $1.06. How much money does Satsuma Pharmaceuticals make? Satsuma Pharmaceuticals (NASDAQ:STSA) has a market capitalization of $35.14 million. The financial services provider earns $-70,060,000.00 in net income (profit) each year or ($2.01) on an earnings per share basis. How can I contact Satsuma Pharmaceuticals? Satsuma Pharmaceuticals' mailing address is 400 OYSTER POINT BOULEVARD SUITE 221, SOUTH SAN FRANCISCO CA, 64080. The official website for the company is www.satsumarx.com. The financial services provider can be reached via phone at 650-410-3200 or via email at cdavis@lifesciadvisors.com. This page (NASDAQ:STSA) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Satsuma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.